BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 9, 2026
Home » Topics » Financings, BioWorld

Financings, BioWorld
Financings, BioWorld RSS Feed RSS

Financings for April 29, 2020

April 29, 2020
Biopharmas raising money in public or private financings, including: Avadel, Bone Therapeutics, Cadent, Hemostemix, Immunomedics, Oric.
Read More

Financings for April 28, 2020

April 29, 2020
Biopharmas raising money in public or private financings, including: Aeglea, Avadel, Avalyn, Biogen, Caladrius, Immunomedics, Kiadis, Neubase.
Read More
Person using calculator and holding Korean won

Korea’s Ministry of Health and Welfare seeks managers for $82M fund

April 28, 2020
By Gina Lee
HONG KONG – The South Korean Ministry of Health and Welfare (MHW) is seeking a manager for its new ₩100 billion (US$81.63 million) private equity fund, which aims to help domestic biotech and medical device companies expand into overseas markets.
Read More
Dollar sign in piggy bank

Lifesprout scoops up $28.5M in series A

April 28, 2020
By Liz Hollis
Baltimore-based Lifesprout Inc., a Johns Hopkins University startup, said it has closed a $28.5 million series A financing. It is planning to use the proceeds to support clinical development of therapeutic products from its Regenerative Matrix platform.
Read More
Silhouette made of gears

Compass plots a course to phase III with $80M B round for psilocybin in resistant depression

April 28, 2020
By Cormac Sheridan
DUBLIN – Compass Pathways Ltd. raised $80 million in a series B round to continue its development of the psychedelic drug psilocybin in treatment-resistant depression.
Read More

Financings for April 27, 2020

April 27, 2020
Biopharmas raising money in public or private financings, including: Actym, Actinium, ADC, Cyclacel, Cyclo, Erasca, Evofem, Lifesprout, Lyra, Rome, VBI.
Read More
HKEX building

Akeso reaps $314M via largest IPO on HKEX this year, eyes PD-1-based bispecific

April 24, 2020
By Elise Mak
BEIJING – Pre-revenue Chinese biotech Akeso Inc., of Zhongshan, Guangdong province, launched a high-profile IPO on April 24 in Hong Kong to reap HK$2.4 billion (US$314 million), even though the economy is taking a hard hit from the COVID-19 pandemic.
Read More

Market uncertainty doesn’t hinder Oric’s IPO launch

April 24, 2020
By Lee Landenberger
Oric Pharmaceuticals Inc. stepped into a tough economic climate on Friday when it priced its IPO of 7.5 million shares of common stock at $16 each and won the day as shares (NASDAQ:ORIC) closed at $25.77 each, 61.06% higher than they started.
Read More

Financings for April 24, 2020

April 24, 2020
Biopharmas raising money in public or private financings, including: Caladrius, Lineage Cell, Pluristem.
Read More
Drug vials and syringe

Affinivax raises $120M series B to advance MAPS vaccines and immunotherapies

April 23, 2020
By Michael Fitzhugh
With completion of a $120 million series B financing, Affinivax Inc. said it's poised to advance several new vaccine candidates for hospital-associated infections into the clinic even as its partner, Astellas Pharma Inc., carries its lead pneumococcal vaccine candidate, ASP-3772, through an upcoming phase III program.
Read More
Previous 1 2 … 288 289 290 291 292 293 294 295 296 … 326 327 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing